The effect of exposure to 35,000 ft on incidence of altitude decompression sickness.

INTRODUCTION: Exposure to 35,000 ft without preoxygenation (breathing 100% oxygen prior to decompression) can result in severe decompression sickness (DCS). Exercise while decompressed increases the incidence and severity of symptoms. Clarification of the level of activity vs. time to symptom onset is needed to refine recommendations for current operations requiring 35,000-ft exposures. Currently, the U.S. Air Force limits these operations to 30 min following 75 min of preoxygenation. The objective of this study was to determine the effect of exercise intensity on DCS incidence and severity at 35,000 ft. METHODS: Following 75 or 90 min of ground-level preoxygenation, 54 male and 38 female subjects were exposed to 35,000 ft for 3 h while performing strenuous exercise, mild exercise, or seated rest. The subjects were monitored for venous gas emboli (VGE) with an echo-imaging system and observed for signs and symptoms of DCS. RESULTS: Exposures involving strenuous and mild exercise resulted in higher incidence (p < 0.05) and earlier onset of symptoms (p < 0.05) of DCS than exposure at rest. Mild and strenuous exercise during exposure did not differ in incidence or rate of onset. Incidence at 30 min of exposure was 8% at rest and 23% while exercising. CONCLUSION: The results showed that current guidelines for 35,000-ft exposures keep DCS risk below 10% at rest. Exercise, even at mild levels, greatly increases the incidence and rate of onset of DCS.

Test and evaluation of exercise-enhanced preoxygenation in U-2 operations.

BACKGROUND: Preoxygenation to prevent decompression sickness (DCS) during U-2 reconnaissance flights requires considerable time and occasionally does not provide adequate protection. Increasing preoxygenation within a practical period of time provides marginally increased protection and is not always operationally feasible. Including exercise during preoxygenation to increase muscle tissue perfusion, cardiac output, and ventilation can improve the quality of the denitrogenation. METHODS: A pilot, who reported two cases of DCS during his first 25 U-2 high flights involving cabin altitudes of 29,000-30,000 ft, volunteered to test exercise-enhanced preoxygenation. He performed 10 min of strenuous upper and lower body exercise at the beginning of preoxygenation prior to subsequent high flights without increasing total preoxygenation time. RESULTS: The exercise was performed at 75% of maximal oxygen uptake based on the estimated maximal oxygen uptake determined during an Air Force aerobic fitness test and heart rate. The pilot's next 36 high flights, using exercise-enhanced preoxygenation, were completed with no reports of DCS. CONCLUSIONS: This statistically significant operational test reinforced the laboratory studies. Implementation of this procedure for reducing DCS in susceptible U-2 pilots and collecting additional data from the U-2 pilot population is recommended.

The effect of staged decompression while breathing 100% oxygen on altitude decompression sickness.

INTRODUCTION: Space Shuttle extravehicular activity (EVA) requires decompression from sea level pressure (14.7 psia) to a 4.3 psia (30,300 ft) pressure suit. The transition currently involves altering the shuttle atmosphere to allow shirt-sleeve denitrogenation to occur during a 12 to 36-h staged decompression (SD) at 10.2 psia (9,800 ft) with an oxygen-enriched breathing gas (26.5% oxygen, 73.5% nitrogen). The denitrogenation provides protection from decompression sickness (DCS) during EVA in a 4.3 psia pressure suit. Our goal was to determine the highest altitude at which SD while breathing 100% oxygen (SD100) could provide effective protection from development of DCS symptoms after further decompression to 29,500 ft (4.5 psia). METHODS: There were 30 male subjects exposed to at least 6 of 11 conditions in random order on successive months to 29,500 ft for 4 h while performing mild exercise and being monitored for venous gas emboli (VGE) with an echo-imaging system. The subjects received 15 min of ground-level (GL) preoxygenation and an additional 60 or 120 min of SD100 at one of four altitudes between 8,000 ft (10.9 psia) and 18,000 ft (7.3 psia). Control exposures followed a 75- or 135-min ground-level preoxygenation. RESULTS: During SD100, one case of DCS occurred at 18,000 ft, but not at lower staging altitudes. Higher levels of VGE were observed during SD100 at 18,000 ft than during SD100 at any lower altitude. CONCLUSION: Staged decompression at 16,000 ft and below results in decompression risk during subsequent decompression to 29,500 ft similar to that following equivalent periods of ground-level preoxygenation.

The effectiveness of ground level oxygen treatment for altitude decompression sickness in human research subjects.

BACKGROUND: Current therapy for altitude decompression sickness (DCS) includes hyperbaric oxygen therapy and ground-level oxygen (GLO). The purpose of this paper is to describe the Air Force Research Laboratory experience in the extensive use of GLO for the treatment of altitude DCS in research subjects. METHODS: Data were collected from 2001 altitude chamber subject-exposures. These data, describing DCS symptoms, circulating intracardiac venous gas emboli, and treatment procedures used were collected for each subject exposure and stored in an altitude DCS database. RESULTS: In the database of 2001 subject exposures, 801 subjects (40.0%) were diagnosed with altitude DCS. Subjects reporting DCS symptoms were immediately recompressed to ground level. Of the 749 subjects who received 2 h GLO, 739 (98.7%) resolved completely and required no further treatment. CONCLUSIONS: Although not an operational study, these data provide indirect support for the current USAF guidelines for the treatment of altitude DCS with GLO.

Exercise-induced altitude decompression sickness.

BACKGROUND: It has been known since World War II that exercise at altitude increases incidence of decompression sickness (DCS). However, data on the effects of specific exercise types at altitude are lacking. This research focused on the relative hazards of exercise without motion (isometric, straining) vs. dynamic exercise involving motion. The study also compared arm vs. leg exercise. METHODS: There were 32 healthy male subjects exposed, while resting, to 29,500 ft (8992 m) for 4 h or until DCS occurred, at which time they were brought to ground level. If the subject developed DCS on this exposure, he was exposed in successive months to lower altitudes, using the same procedure, until the subject was free of symptoms for the 4-h exposure. At this symptom-free altitude, as low as 20,000 ft (6096 m), the subject performed isometric arm, isometric leg, dynamic arm and dynamic leg exercises at less than 10% of maximal oxygen consumption, each during separate exposure months. Precordial venous gas emboli (VGE) were monitored every 20 min during each exposure with a Hewlett-Packard SONOS 1000 Echo Imaging System. RESULTS: Dynamic arm, dynamic leg, isometric arm, and isometric leg exercise induced DCS in 50%, 38%, 41% and 31% of the subjects, respectively. VGE incidence varied from 47-66%. No significant differences in DCS or VGE were found. CONCLUSIONS: Under our test conditions, there was no difference between dynamic and isometric exercise in eliciting DCS. Exercise during exposure to the symptom-free altitude for 4 h produced a 40% incidence DCS.

Preoxygenation time versus decompression sickness incidence.

Preoxygenation, breathing 100% oxygen prior to decompression, has been used for well over half of this century to reduce decompression sickness (DCS) incidence. Duration of preoxygenation has been reported to be inversely related to subsequent DCS incidence. A direct comparison of DCS incidence at 30,000 ft versus preoxygenation time is needed to allow better-informed decisions regarding the cost vs. benefit of increasing preoxygenation time to prevent DCS. To obtain such a comparison, we accomplished a retrospective study of exposures to 30,000 ft (226 mm Hg; 4.37 psia) while performing mild exercise. The 86 male exposures were preceded by preoxygenation times of one to four hours. Venous gas emboli (VGE) and DCS symptom development were monitored and recorded. Although more protection was demonstrated with increasing preoxygenation time, the cost-to-benefit ratio also increases with each additional increment of preoxygenation time. The diminishing return of increasing preoxygenation to reduce DCS would eventually impact mission planning and crew duty limitations. Alteration in the physiology of denitrogenation, such as inclusion of exercise during preoxygenation, may provide better and more cost-effective DCS protection than simply increasing preoxygenation time.

A loglogistic model for altitude decompression sickness.

BACKGROUND: Altitude decompression sickness (DCS) is a potential hazard encountered during high altitude flights or during extravehicular activity in space. In this study, the loglogistic distribution was used to model DCS risk and symptom onset time. METHODS: The Air Force Research Laboratory, Brooks AFB, TX, has conducted studies on human subjects exposed to simulated altitudes in hypobaric chambers. The dataset from those studies was used to develop the DCS models and consisted of 975 subject-exposures to various altitudes, preoxygenation times, and exercise regimens. Since the risk of DCS is known to increase over time at altitude, and then decrease because of denitrogenation, the loglogistic model was fit to the data. The model assumes that the probability of DCS depends on several risk factors. Maximum likelihood estimates of the parameters were obtained using the statistical software package SAS. Cross validation techniques were provided to examine the goodness of fit of the model. RESULTS: The fitted model indicated that altitude, ratio of preoxygenation to exposure time, and exercise were the most significant risk factors. The model was used to predict the risk of DCS for a variety of exposure profiles. The predicted probability of DCS agreed very closely with the actual percentages in the database. CONCLUSION: The loglogistic distribution was found to be appropriate for modeling the risk of DCS. Based on the cross validation and validation results, we conclude that this model provides good estimates of the probability of DCS over time.

An abrupt zero-preoxygenation altitude threshold for decompression sickness symptoms.

INTRODUCTION: The altitude threshold for decompression sickness (DCS) symptoms has been variously described as being 18,000 ft (5,487 m) to above 25,000 ft (7,620 m). Safety and efficiency of aerospace operations require more precise determination of the DCS threshold. METHODS: Subjects were 124 males who were exposed to simulated altitudes (11 at 11,500 ft; 10 at 15,000 ft; 8 at 16,500 ft; 10 at 18,100 ft; 10 at 19,800 ft; 20 at 21,200 ft; 20 at 22,500 ft; 10 at 23,800 ft, and 25 at 25,000 ft) for 4 to 8 h. All breathed 100% oxygen beginning with ascent. Subjects were monitored for precordial venous gas emboli (VGE) and DCS symptoms. Probit curves representing altitude vs. incidence of DCS symptoms and VGE allowed estimation of respective risk. RESULTS: VGE were first observed at 15,000 ft with increasing incidence at higher altitudes; over 50% at 21,200 ft and 70% or higher at 22,500 ft and above. The lowest altitude occurrence of DCS was a 5% incidence at 21,200 ft. At 22,500 ft, the DCS incidence abruptly climbed to 55%. CONCLUSION: A 5% threshold for DCS symptoms was concluded to be 20,500 ft under the conditions of this study. The abrupt increase in DCS symptoms, with zero-preoxygenation exposure above 21,200 ft implies a need for reconsideration of current USAF and FAA altitude exposure guidance.

A new preoxygenation procedure for extravehicular activity (EVA).

A 10.2 psi staged-decompression schedule or a 4-hour preoxygenation at 14.7 psi is required prior to extravehicular activity (EVA) to reduce decompression sickness (DCS) risk. Results of recent research at the Air Force Research Laboratory (AFRL) showed that a 1-hour resting preoxygenation followed by a 4-hour, 4.3 psi exposure resulted in 77% DCS risk (N=26), while the same profile beginning with 10 min of exercise at 75% of VO2peak during preoxygenation reduced the DCS risk to 42% (P<.03; N=26). A 4-hour preoxygenation without exercise followed by the 4.3 psi exposure resulted in 47% DCS risk (N=30). The 1-hour preoxygenation with exercise and the 4-hour preoxygenation without exercise results were not significantly different. Elimination of either 3 hours of preoxygenation or 12 hours of staged-decompression are compelling reasons to consider incorporation of exercise-enhanced preoxygenation.

Relationship between age and susceptibility to altitude decompression sickness.

BACKGROUND: Susceptibility to altitude decompression sickness (DCS) is influenced by a multitude of factors including, potentially, an individual's age. Previous attempts by authors to determine the effect of age on DCS susceptibility have produced conflicting results. The purpose of this study was to try to clarify that conflict and to quantify the impact of age on DCS risk. METHODS: We examined the Armstrong Laboratory DCS Hypobaric Research Database containing data on 1299 subject flight exposures conducted from 1983-94. Subjects were from 18-45 yr of age. Exposure altitudes ranged from 11,500 ft (3505 m) to 30,000 ft (9144 m). The duration of exposure varied from 3-8 h and preoxygenation time ranged from 0-2 h and 15 min. Data were compiled according to seven age groups. RESULTS: The results show a significant three-fold increase in susceptibility between the age group 18-21 and the group > 42 yr of age. The results also show a trend toward increased susceptibility between the 18-21 group and the groups between 26 and 41 yr of age. However, there was no significant change within the range of 26-41 yr. CONCLUSION: There is a trend toward increased DCS susceptibility with increasing age, with a particularly strong trend for individuals over 42 yr of age.

Left ventricular gas emboli in six cases of altitude-induced decompression sickness.

BACKGROUND: Ultrasonic techniques have demonstrated venous gas emboli (VGE) during exposure to high altitude. VGE per se have not been considered clinically hazardous. Arterial gas emboli (AGE), however, are viewed with great concern. The crossing-over of venous gas to the arterial circulation has not previously been seen in human subjects at altitude. This transfer may occur via either intracardiac defects, pulmonary shunts, or the pulmonary microcirculation. METHODS: A non-invasive ultrasonic echo imaging Doppler system was used to monitor volunteer human subjects for gas emboli simultaneously in the right and left sides of the heart at simulated altitude in a chamber. Subjects found to have gas cross-over were evaluated for septal defects with either transthoracic or transesophageal echocardiography. RESULTS: Previously unreported left ventricular gas emboli were observed with echo imaging in six subjects at altitude. In all six cases, at the time of AGE onset, the VGE scores were high from all monitored sites. Three subjects had no septal defect, another had a small sinus venosus defect, a third had a patent foramen ovale, and one was not available for evaluation. Five of the cases became symptomatic at the time of AGE onset. CONCLUSIONS: Operational altitude exposures known to elicit high VGE counts in the majority of people should be avoided because of an increased risk of right-to-left gas cross-over and resulting potential for severe cerebral symptomatology.

The initial signs and symptoms of altitude decompression sickness.

BACKGROUND: With the potential for higher aircraft and cabin altitudes, the way in which altitude decompression sickness (DCS) presents continues to be of interest. The majority of previous papers on the symptomatology of DCS are retrospective reviews of patients treated hours or days post-exposure. The initial presentation while still at altitude is the form of DCS that aircrew must be able to recognize in order to respond correctly. This paper reports the initial manifestations of DCS that occurred during a series of prospective hypobaric chamber studies. These studies had been specifically designed to investigate DCS. METHODS: This paper presents a prospective analysis of DCS symptoms from 447 subjects, recorded over an 11-yr period at the Armstrong Laboratory (AL), and is an attempt to provide an accurate representation of the initial presentation of altitude DCS. RESULTS: Of the 447 cases, 83.2% had musculoskeletal involvement, 2.7% had chokes, 2.2% skin manifestations, 10.8% paresthesia, and 0.5% frank neurological features. CONCLUSIONS: The most common presenting feature was musculoskeletal, with knee pain predominating (occurring in 70% of these cases). A very low incidence of neurological features was seen in the AL database, which was in contrast to data from many other sources. Reasons for this difference may include the use of preoxygenation and the policy of prompt recompression upon symptom development at AL. There is also the possibility that individuals in the training and operational environments are more likely to report frank neurological involvement than other forms of DCS.

Exercise-enhanced preoxygenation increases protection from decompression sickness.

INTRODUCTION: Prevention of decompression sickness (DCS) during exposure to altitude equivalents of 30,000 ft (9144 m) requires extensive denitrogenation. In preparation for extravehicular activity (EVA), present NASA policy is to denitrogenate using a 10.2 psia staged decompression of the entire shuttle for at least 12 h, including 100 min of preoxygenation (breathing 100% oxygen at 14.7 psia prior to decompression), before decompression to the 4.3 psia (30,000 ft; 9144 m) suit pressure. This staged decompression provides the same or better protection from DCS as a 3.5- or 4-h preoxygenation used on earlier Shuttle EVA's. For high altitude reconnaissance flights at similar cockpit altitudes, a 1-h preoxygenation is currently required. METHODS: We have investigated the use of a 1-h and a 15-min preoxygenation period, each beginning with 10 min of dual-cycle ergometry performed at 75% of each subject's peak oxygen consumption (VO2peak) to enhance preoxygenation efficiency by increasing perfusion and ventilation. Male subjects accomplished a 1-h preoxygenation with exercise, a 15-min preoxygenation with exercise, or a 1-h resting preoxygenation before exposure to 4.3 psia for 4 h while performing light to moderate exercise. RESULTS: Incidence of DCS following the 1-h preoxygenation with exercise (42%; n = 26) was significantly less than that following the 1-h resting preoxygenation (77%; n = 26). Incidence and onset of DCS following the 15-min preoxygenation with exercise (64%; n = 22) was not significantly different from the incidence following the 1-h resting control. CONCLUSION: Preoxygenation with exercise has been shown to provide significantly improved DCS protection when compared with resting preoxygenation.

Prevalence of decompression sickness among U-2 pilots.

BACKGROUND: Though it is rarely reported, decompression sickness (DCS) is an expected risk for U-2 aviators. The potential for chronic sequelae of untreated DCS in this population has never been addressed. METHODS: After conducting a preliminary survey at an active-duty U-2 squadron, a cohort of 416 U-2 pilots (active-duty and retired) were mailed two sequential anonymous surveys to assess demographic data, career prevalence of DCS symptoms, and overall health status with an emphasis on chronic musculoskeletal problems. RESULTS: The response rate for each mail-in survey was over 60%. During their career, 75.5% of pilots experienced DCS symptoms such as joint pain, skin manifestations, and/or various neurological problems. Symptoms generally started during flight and resolved upon descent. Many pilots voluntarily increased their oxygen prebreathing time, or inflated the pressure suit during flight to prevent or treat symptoms. At some point in their career 12.7% of those experiencing symptoms either altered the flight profile or aborted a mission as a result. The association of past DCS with current arthritic problems was not statistically significant. CONCLUSIONS: The career prevalence of DCS symptoms in U-2 pilots is higher than previously reported, and these symptoms sometimes affect mission completion. We found no evidence that chronic musculoskeletal sequelae (e.g., arthritis or dysbaric osteonecrosis) are causally associated with DCS in this population.

Prevention of decompression sickness in current and future fighter aircraft.

United States Air Force oxygen regulators set to "NORMAL OXYGEN" deliver up to 60% nitrogen to the pilot at cockpit altitudes of 15,000 to 20,000 ft (4573-6096 m). Research chamber exposure to these altitudes while breathing 50% nitrogen has resulted in high grades of venous gas emboli. Expansion of existing gas emboli following an unplanned decompression to ambient aircraft altitude (e.g., loss of canopy) could result in rapid development of decompression sickness (DCS) symptoms. To reduce this potential problem, regulators in current fighters should be set to "100% OXYGEN" until descent from cruise to increase denitrogenation. The United States' Advanced Tactical Fighter and the European Fighter Aircraft may be designed to cruise above 50,000 ft (15,240 m), where cockpit altitudes exceed 20,000 ft with a 5-psi differential (psid) cockpit pressurization schedule. Increasing cockpit differential pressure to 7 psid while breathing 100% oxygen would greatly reduce the chance of significant emboli formation and the potential for DCS, but would slightly elevate the risks associated with pulmonary overpressure during rapid decompression.

Breathing 100% oxygen compared with 50% oxygen: 50% nitrogen reduces altitude-induced venous gas emboli.

The risk of venous gas emboli (VGE) and decompression sickness (DCS) must be determined before selection of the lowest pressure for an extravehicular activity (EVA) pressure suit which eliminates the requirement for prebreathing. In earlier studies, use of a 50% oxygen:50% nitrogen breathing mixture (50:50 mix) during 139 zero-prebreathe decompressions of male subjects to 8.3-7.8 psia resulted in 51 instances of severe VGE and one case of DCS. Our current study investigated effects of 40 zero-prebreathe decompressions of male subjects to 8.3-6.8 psia for 6 h while breathing 100% oxygen and performing moderate exercise. No DCS symptoms were observed. Severe VGE were not detected at 8.3 psia, but were present during 10%, 20%, and 40% of the exposures at 7.8, 7.3, and 6.8 psia, respectively. Zero-prebreathe decompression while breathing 100% oxygen results in significantly lower VGE and DCS risk levels than while breathing a 50:50 mix. Our results show that 7.3 psia EVA pressure suits with 100% oxygen should be safer than 8.3 psia suits with a 50:50 mix.

Cardiac arrest from gas embolism in scuba diving.

The case of a scuba diver who suffered a cardiac arrest is presented. The history of a short, lucid interval after surfacing followed by cardiac arrest, the finding of hemoptysis, and the characteristic response to recompression therapy are consistent with the diagnosis of gas embolism. The clinical presentation and pathophysiology of gas embolism are discussed, and an approach to emergency stabilization and definitive management of gas embolism is reviewed, with emphasis on cardiac arrest.

Pathophysiology of bends and decompression sickness. An overview with emphasis on treatment.

Current concepts in the pathophysiology of decompression sickness are reviewed. Mild, moderate, and severe forms of this syndrome resulting from gaseous and lipid emboli are described. Therapy is aimed at restoring or specifically treating each alteration. Plasma volume deficit is restored by colloidal re-expansion. Decompression sickness is partially treated when recompression alone is used. Blood lipid alterations are managed by use of antilipemic agents. Dextran is mentioned. Divers at depths of 61 m display changes in hematocrit, platelet, and blood lipid profiles. Cord paralysis may occur from bubbles in the vena cava. Retrograde migration blocks the venous circulation of the spinal cord. Ultrasonic devices can detect "silent" bubbles during decompression. Recompression, when available, is a lifesaving treatment for diving accidents involving saturation diving. Air embolism is discussed. Monitoring emboli by EEG and fundoscopy are reported.